Geron at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Geron brings 1 presentation to ASH 2026 in New Orleans, and exhibits at Booth 1929. Its program centres on myelofibrosis and myelodysplastic syndromes. It supports symposia on myeloproliferative neoplasms and presents research on imetelstat dosing in lower-risk MDS.
| Organization | ASH 2026 Attendance |
|---|---|
Geron Foster City, CA | |
Biopharmaceutical company marketing imetelstat (RYTELO), a telomerase inhibitor for lower-risk MDS, and studying it in myelofibrosis. | Booth Exhibiting at Booth 1929 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 3:00pm–6:00pm A Case-Based Exploration of Current and Future Directions in Myelofibrosis – Where We Are, Where We’re Going Real patient cases showing how experts treat myelofibrosis today, paired with reviews of current data and ongoing research on emerging therapies. Symposium Fri Dec 11 3:00pm–6:00pm Cases and Conversations: Applying Emerging Evidence to Real-World Care in Myeloproliferative Neoplasms Choosing among new myeloproliferative neoplasm drugs, including Janus kinase and telomerase inhibitors, hepcidin mimetics, and calreticulin-targeted antibodies. Symposium Fri Dec 11 3:00pm–6:00pm MDS in the Modern Era: Getting Ahead of the 8-Ball Moving myelodysplastic syndrome care toward early disease-modifying drugs, with hypomethylating agents for higher-risk disease and wider transplant access. |
Find decision makers at Geron
Tell us what you sell and we’ll find the people at Geron most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction